To include your compound in the COVID-19 Resource Center, submit it here.

Trillium reports Phase I data for TT-621 in mycosis fungoides

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported preliminary data from 10 patients with relapsed or refractory mycosis fungoides in the Phase I TTI-621-02

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE